A Phase 3 interventional study of Oxycodone extended-release in Moderate-to-severe Chronic Noncancer Pain, sponsored by Egalet Ltd. Completed at 39 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2018-03-05.
Sponsored by Egalet Ltd · Phase 3, Interventional, and Treatment
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Egalet Ltd is the lead sponsor of 18 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Egalet abuse-deterrent, extended-release oxycodone tablet
Drug: Oxycodone extended-release
Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment
Time frame: 1 year
Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period
Time frame: 1 year
This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Egalet Ltd